- Category: TMAU - Front Page
- Published on Thursday, 12 April 2012 10:38
- Written by Site Admin
- Hits: 20462
Trimethylaminuria (TMAU), also known as fish odour syndrome or fish malodour syndrome is a rare metabolic disorder where the body loses the ability to properly breakdown timethylamine (TMA) found in certain foods into timethylamine oxide (TMAO)
Trimethylamine then builds up and is released in the person's sweat, urine, and breath, giving off a strong fishy odor.
The first step is to contact your own GP who may then refer you for a urine test. This test will help to determine if you have Trimethylaminuria.
Diagnosis is also possible through gene sequencing (done via a blood test).
Our experience is that many GPs have never heard of this condition and therefore it may help to provide your GP with this website address prior to your attendance.
A quick look around the forums will reveal that it has taken many people years before they were diagnosed. Hopefully this will begin to change with increased media exposure.
Please read/search the forums, if you have any questions about getting diagnosed feel free to post a question if it's not been answered.
Further Information: (Reproduced with permission)
Author: N. Manning, Principal Clinical Scientist, Sheffield Children's Hospital
Disorder nomenclature / synonyms:
- Trimethylaminuria (TMAU)
- Primary TMAU (TMAU1) (Inherited FMO3 deficiency)
- Secondary TMAU (TMAU2)
- Fish Odour Syndrome (FOS) (Fish Malodour Syndrome)
- Primary FOS / Secondary FOS
- Flavin-containing mono-oxygenase type 3 (FMO3) deficiency.
Trimethylaminuria (TMAU) is a disorder defined by the excessive urinary excretion of the volatile tertiary amine trimethylamine (TMA). This reflects an increase in body fluids which results in TMAU patients exuding the odour of rotten fish (similar to ammonia), as the excess TMA is excreted in sweat. Body odour of rotten fish is not unsurprisingly accompanied by the same odour on the breath of TMAU sufferers.
TMAU is therefore a potentially distressing condition of social exclusion resulting in depression and other psychological problems. Patients may start to show signs of the condition at various ages from infancy to adulthood depending mainly on whether the disorder is inherited or acquired.
The inherited form of TMAU is known as Primary TMAU or TMAU1. The result of a faulty recessive gene, TMAU1 patients have impaired activity of a liver enzyme known as FMO3 (flavin-containing mono-oxygenase type 3). FMO3 oxidises chemical compounds and has a wide range of substrates including many drugs. TMA is oxidised to the non-odourous TMA-oxide (TMO) by FMO3 which can then be excreted. TMA itself is generated in the large intestine by bacteria which break down compounds such as choline (in meat, liver, eggs and beans/peas), carnitine (meat) and TMO from seafood (hence TMA from rotting fish).
TMAU1 therefore results from FMO3 deficiency with an increase in the ratio of TMA to TMO in urine which can be used for diagnosis.
Due to the low specificity of FMO3 and the large number of drugs detoxified, TMAU1 patients may suffer from adverse drug reactions (eg with codeine; tamoxifen; ketoconazole; nicotine; cimetidine; ranitidine; phenothiazine). Hypertension may result from ingestion of red wine and cheese (and chocolate), which produce the neurotransmitter tyramine, another FMO3 dependent compound. Many people suffer from migraines associated with tyramine containing foods and perhaps FMO3 deficiency may explain some of these cases, but overall this demonstrates the adverse medical consequences as well as the odour related psychosocial aspects.
The acquired form of TMAU is covered by the term Secondary TMAU or TMAU2 where TMA excretion is high even though FMO3 activity is normal.
Most TMAU2 patients produce too much TMA from intestinal bacteria due to excessive bacterial growth of TMA-generating species. The TMA burden is so great that FMO3 oxidation is not enough to convert all the TMA. This problem may be exacerbated by intestinal structural problems such as ‘blind loops’ or post operative complications. TMAU2 usually presents in adulthood although children have been known to acquire excessive TMA-producing bacteria with the resultant odour.
The diagnosis of TMAU2 depends on the detection of increased urinary TMA and TMO with a normal TMA/TMO ratio indicating normal oxidation by FMO3.
Some TMAU2 patients may have liver or kidney disease which results in a TMAU1-like pattern of excretion. Importantly this may also occur with a urinary tract infection (UTI) which results in TMA being produced directly into the urine giving a false positive result. Whenever results suggest TMAU1, therefore, UTI must always be excluded by microbial analysis before a TMAU1 diagnosis is confirmed in a follow-up sample.
Treatment of both TMAU1 and TMAU2 is based on diet to restrict the sources (precursors) of TMA (eg choline) and antibiotics (eg metranidazole, neomycin or amoxicillin) to eliminate the TMA-producing bacteria. TMAU2 can in fact be cured by eradication of the excess bacteria, although stubborn colonies may regrow to excess and require further courses of treatment.
TMAU1, as a genetic defect, cannot be completely cured although therapy (dietary and antibiotic) can successfully control the patient’s TMA to a less odorous level. Patient’s residual enzyme activity is variable depending on the specific mutation and as such trials with the cofactor riboflavin have been tried with some success. Milder TMAU1 patients can, however, reduce their TMA to almost normal values with just diet and periodic antibiotic therapy. Other forms of therapy are based on the neutralisation of TMA chemically. Skin creams with a comparatively low pH (5.0) may neutralise TMA which is alkaline. This creates a non-volatile salt of TMA which lessens any odour and can be washed off by the patient later. The other solution lies in deodorising tablets such as ‘activated charcoal’ or copper-chlorophyllin complex (marketed as ‘Nullo’). These ‘internal deodorants’ have been successfully used for many years and would be ideal for more severely affected TMAU1 patients.
Testing for TMAU
We offer a urine test for trimethylamine (TMA) and the oxide of TMA. The technique used is gas chromatography – mass spectrometry. This enables us to diagnose TMAU1 and TMAU2. A positive result is always followed up – with a routine second test after a report of the initial findings. The turnaround time for the test is currently 4 weeks or less. A GP or physician referral is essential, but we can offer advice by phone or email about how to start the process.
DNA analysis for the FMO3 gene is also available with a turnaround time of 8 weeks. This will help confirm the diagnosis of TMAU1 or TMAU2 and facilitate further family investigations if required.